Nektar Therapeutics Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31)
Nektar Therapeutics (NKTR) reported Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) of $12.58 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Notes › Equity
us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 · last filed 2019-11-07
- Nektar Therapeutics cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2018-03-31 was $12.58M.
- Nektar Therapeutics cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for fiscal 2018 was $12.58M.
| Period end | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 3 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 12 month |
|---|---|---|
| 2018-12-31 | $12.58M 10-K · filed 2019-03-01 | |
| 2018-03-31 | $12.58M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |